Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.48 |
| ▸ | HPGD | P15428 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1909605 | 0.90 | KLKB1 (0.61) | KLKB1KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL554857 | 0.86 | KLKB1 (0.61) | KLKB1KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2819485 | 0.82 | KLKB1 (0.55) | KLKB1KDM4EGRM2MEN1KMT2A | |
| SCHEMBL1909166 | 0.80 | GRM2 (0.53) | KLKB1KDM4ECYP1A2CYP3A4GRM2 | |
| SCHEMBL553953 | 0.79 | KLKB1 (0.58) | KLKB1GRM2 | |
| SCHEMBL28595790 | 0.79 | ESR1 (0.55) | KLKB1KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2821953 | 0.79 | LMNA (0.54) | KLKB1GRM2HSD17B10ALDH1A1MAPT | |
| SCHEMBL2824923 | 0.78 | GRM2 (0.57) | KLKB1GRM2KMT2AHPGDALOX15 | |
| SCHEMBL30755417 | 0.78 | GRM2 (0.57) | KLKB1GRM2KMT2AHPGDALOX15 | |
| SCHEMBL3606832 | 0.78 | SMN1; SMN2 (0.57) | KLKB1KDM4ECYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-2601189-B1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2601189-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | Novartis AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| CN-103080104-A | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | TPMT, REN, PNMT | KLKB1 4526/4885KDM4E 927/4885CYP1A2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.